John Lasala

Two-year clinical outcomes of paclitaxel-eluting stents for in-stent restenosis in patients from the ARRIVE programme

• Lee M,
• Yang T,
• Lasala J,
• Cox D,
• Bowman T,
• Starzyk R,
• Dawkins K

EuroIntervention 2011;7:314-322

Published in Volume 7 Number 3, July 2011

A clinical risk score for the prediction of very late stent thrombosis in drug eluting stent patients

• Baran K,
• Lasala J,
• Cox D,
• Mascioli S,
• Song A,
• Deshpande M,
• Jacoski M,
• Dawkins K

EuroIntervention 2011;6:949-954

Published in Volume 6 Number 8, March 2011

Clinical outcomes post implantation of the paclitaxel-eluting stent in saphenous vein graft lesions in routine clinical practice: insights from the ARRIVE 1 and ARRIVE 2 registries

• Brilakis E,
• Berger P,
• Lasala J,
• Cox D,
• Starzyk R,
• Dawkins K,
• Baim D

Published in Volume 5 Supplement E, May 2009

Expanded use of the TAXUS Express Stent: two-year safety insights from the 7,500 patient ARRIVE Registry programme

• Lasala J,
• Cox D,
• Lewis S,
• Tadros P,
• Haas R,
• Schweiger M,
• Chhabra A,
• Untereker W,
• Starzyk R,
• Mascioli S,
• Dawkins K,
• Baim D

EuroIntervention 2009;5:67-77

Published in Volume 5 Number 1, May 2009